What does CUSIP 22663K107 represent in this 13F holders report?

CUSIP 22663K107 is the security identifier for CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK used to aggregate holder disclosures.

How many institutions held CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK in Q1 2019?

62 institutional investors reported CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK for Q1 2019. Use the holders table for investor-level position and value details.

Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX)

CUSIP: 22663K107

Q1 2019 13F Holders as of 31 Mar 2019

Security type / class: Equity / COMMON STOCK
Total 13F shares: 17,737,322
Total 13F value: $403,697,060
Share change: +948,577
SEC-reported price per share: $22.76
Number of holders: 62
Value change: +$20,738,652
Number of buys: 40
Number of sells: 13
Shares outstanding: 102,849,349

Security key

22663K107

Report period

Q1 2019

Institutions

Top holders

CRNX full security history Ownership snapshot Full 13F holder table Crinetics Pharmaceuticals, Inc. SEC filings Crinetics Pharmaceuticals, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Vivo Capital, LLC

Disclosed value leader

Vivo Capital, LLC

Comparable rows

15/15

Latest evidence

31 Dec 2018

13F Lead comparable stake: 3.7% Showing 1-6 of 15 holder rows.

Quick read

Vivo Capital, LLC leads the comparable SEC ownership view at 3.7%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Vivo Capital, LLC's linked filing trail.

Comparable ownership Top 5

Vivo Capital, LLC 3.7%

FMR LLC 2.9%

PERCEPTIVE ADVISORS LLC 2.5%

ORBIMED ADVISORS LLC 1.9%

RA CAPITAL MANAGEMENT, L.P. 1.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Vivo Capital, LLC	13F Company 13F	3.7%	$113,727,000 3,792,169 shares	—	31 Dec 2018
FMR LLC	13F Company 13F	2.9%	$88,126,000 2,938,539 shares	—	31 Dec 2018
PERCEPTIVE ADVISORS LLC	13F Company 13F	2.5%	$77,612,000 2,587,953 shares	—	31 Dec 2018
ORBIMED ADVISORS LLC	13F Company 13F	1.9%	$57,409,000 1,914,282 shares	—	31 Dec 2018
RA CAPITAL MANAGEMENT, L.P.	13F Company 13F	1.8%	$56,238,000 1,875,209 shares	—	31 Dec 2018
BlackRock Finance, Inc.	13F Company 13F	0.67%	$20,789,000 693,172 shares	—	31 Dec 2018

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2019

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

17,737,322

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2019 vs Q1 2019 Across Filers

Q1 2019 holders

Holder diff

Investor	Q1 2019 Shares	Q1 2019 Shares	Share Diff	Share Chg %	Q1 2019 value	Q1 2019 value	Value change	Value Chg %